An OPTUM study reveals that blue light cystoscopy is cost-neutral compared to traditional white light cystoscopy in bladder cancer management, enhancing detection without increased costs.

The BRAVO study reveals that while blue light cystoscopy incurs higher initial costs, lower recurrence rates lead to overall cost neutrality in bladder cancer care.

At AUA2025, Photocure ASA showcased Blue Light Cystoscopy's significant role in improving bladder cancer management and patient decision-making.

At the EAU 2025 congress, Photocure ASA highlights significant advantages of Blue Light Cystoscopy in managing bladder cancer and reducing recurrence rates.

The BRAVO study published by Photocure ASA shows that Blue Light Cystoscopy significantly reduces bladder cancer recurrence risk. This real-world evidence strengthens prior clinical findings.

A recent publication sheds light on the significant benefits of Blue Light Cystoscopy in reducing the risk of bladder cancer recurrence, showing a promising 38% reduction compared to white light methods.

Photocure ASA presented significant advancements in bladder cancer treatment through Blue Light Cystoscopy at ASCO GU 2025, focusing on patient outcomes.

Photocure ASA unveils groundbreaking findings on Blue Light Cystoscopy at ASCO GU 2025, highlighting its significance in bladder cancer management.